The eotaxin increase was significantly lower in the treated groups compared to the BD group: Coversin group 3105 pg/mL (1921–4289) (p = 0.007), anti-CD14 group 1933 pg/mL (1741–2246) (p < 0.0001) and the dual treatment group 2256 pg/mL (1692–2821) (p = 0.0003) (Fig. 3A). Here, CCL11 is linked to Behcet disease.